Who
William D. Waddill
Director
Company insider
Files Form 4 as: Director, Protagonist Therapeutics; Director, Annexon; Director, Arrowhead Pharmaceuticals; Director, Turnstone Biologics; Sr. VP & CFO, Calithera Biosciences; SVP & Chief Financial Officer, OncoMed Pharmaceuticals.
In numbers
- Trades disclosed
- 112
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $15.1M
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 17 Jul 2013
- Last trade
- 23 Jun 2026
- Last filed
- 25 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jun 2026filed 25 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $149K9,000 at $16.54 | filing |
| 23 Jun 2026filed 25 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M9,000 at $117.94 | filing |
| 23 Jun 2026filed 25 Jun 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,000 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,000 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $149K9,000 at $16.54 | filing |
| 23 Jun 2026filed 25 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M9,000 at $117.94 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $35K3,000 at $11.80 | filing |
| 10 Jun 2026filed 11 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $99K6,000 at $16.54 | filing |
| 10 Jun 2026filed 11 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $969K9,000 at $107.68 | filing |
| 10 Jun 2026filed 11 Jun 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,000 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,000 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $35K3,000 at $11.80 | filing |
| 10 Jun 2026filed 11 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $99K6,000 at $16.54 | filing |
| 10 Jun 2026filed 11 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $969K9,000 at $107.68 | filing |
| 29 May 2026filed 1 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $106K9,000 at $11.80 | filing |
| 29 May 2026filed 1 Jun 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $897K9,000 at $99.64 | filing |
News
Comparing Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX)PTGX · dailypolitical.com · 22 Oct 2026Head-To-Head Review: DBV Technologies (NASDAQ:DBVT) vs. Arrowhead Pharmaceuticals (NASDAQ:ARWR)ARWR · dailypolitical.com · 21 Oct 2026Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus Sera Prognostics (NASDAQ:SERA) Head to Head ReviewARWR · themarketsdaily.com · 18 Oct 2026Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by Wall Street Zen to BuyPTGX · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name William D. Waddill; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.